Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?

Phelan, Mary; Anzures-Cabrera, Judith; Carlile, David J; Rowell, Lucy; Kuhlmann, Olaf; Arold, Gerhard; Robson, Richard; Bentley, Darren

Phelan, Mary; Anzures-Cabrera, Judith; Carlile, David J; Rowell, Lucy; Kuhlmann, Olaf; Arold, Gerhard; Robson, Richard; Bentley, Darren.

Affiliation

Phelan M; Department of Clinical Pharmacology, Roche Products Ltd, Shire Park, Welwyn Garden City AL7 1TW, UK. mary.phelan@roche.com

Clin Pharmacokinet ; 52(4): 255-65, 2013 Apr.

Article in En | MEDLINE | ID: mdl-23400900

Subject(s)

Anticholesteremic Agents/pharmacokinetics; Kidney Diseases/metabolism; Liver Diseases/metabolism; Sulfhydryl Compounds/pharmacokinetics; Adolescent; Adult; Aged; Amides; Anticholesteremic Agents/adverse effects; Anticholesteremic Agents/blood; Anticholesteremic Agents/urine; Esters; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Regression Analysis; Sulfhydryl Compounds/adverse effects; Sulfhydryl Compounds/blood; Sulfhydryl Compounds/urine; Tissue Distribution; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sulfhydryl Compounds / Kidney Diseases / Liver Diseases / Anticholesteremic Agents Type of study: Clinical_trials / Diagnostic_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Pharmacokinet Year: 2013 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google